The Role of Ceus in the Characterization of Focal Liver Lesions Indeterminate to Second-level Methods

Launched by IRCCS AZIENDA OSPEDALIERO-UNIVERSITARIA DI BOLOGNA · Mar 10, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a method called Contrast-Enhanced Ultrasound (CEUS) to see how well it can help doctors determine whether certain liver growths, known as focal liver lesions, are benign (not harmful) or malignant (cancerous). Sometimes, other imaging tests like CT scans, MRIs, or PET scans don’t provide clear answers about these lesions, and this study aims to find out if CEUS can provide more accurate information.

To participate in this trial, individuals need to be at least 18 years old and have had a CEUS in the past six months where other imaging tests were inconclusive. Participants will undergo the CEUS procedure, and they will need to give their consent to join the study. It's important to note that people who cannot have the ultrasound for technical reasons or who are allergic to the contrast fluid used in the ultrasound will not be eligible. This study is currently recruiting participants of all genders, and it hopes to improve the way doctors understand and treat liver lesions in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≥18 years.
• • CEUS performed performed in the last 6 months a CT, MRI and/or PET not decisive in characterizing a liver lesion.
• • Obtaining informed consent.
• Exclusion Criteria:
• • Technical impossibility to perform the ultrasound evaluation.
• • Documented allergy to the ultrasound contrast medium.